Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03460067 · ClinicalTrials.gov registry record · NA
Omission of Radiation in Patients With Her-2 Positive Breast Cancer
A NA study of HER2-positive Breast Cancer, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03460067 is a NA study of HER2-positive Breast Cancer that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 12 participants, below the 239-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03460067, a NA study of HER2-positive Breast Cancer, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to describe the rate of local control in patients with her-2 positive early stage breast cancer with a complete response to chemotherapy and lumpectomy alone.
Conditions Studied
Interventions
- RADIATION Omission of Radiation
Study Locations (1)
Kansas
- University of Kansas Medical Center/ Cancer Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-02-23 |
| Est. Completion | 2027-07-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03460067
The ClinicalTrials.gov registry entry for NCT03460067 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Omission of Radiation is the first listed.
NCT03460067 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT03460067 about?
NCT03460067 is a clinical study titled "Omission of Radiation in Patients With Her-2 Positive Breast Cancer". The primary objective of this study is to describe the rate of local control in patients with her-2 positive early stage breast cancer with a complete response to chemotherapy and lumpectomy alone.
What is the current status of trial NCT03460067?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2018-02-23. Estimated completion is 2027-07-16.
What conditions does trial NCT03460067 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer.
What interventions are being tested in trial NCT03460067?
The interventions under investigation include: Omission of Radiation (RADIATION).
Who is sponsoring clinical trial NCT03460067?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03460067 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NearWave Optical Molecular Monitoring
RECRUITING · NA
-
Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer
RECRUITING · NA
-
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
RECRUITING · NA
-
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
ACTIVE NOT RECRUITING · NA
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
TRUDI: TDXD+Durva in HER2+/Low IBC
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.